Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine with anticonvulsant properties. It is a 1,5-benzodiazepine, differing structurally from the more common 1,4-benzodiazepines. It has a longer half-life and a less pronounced sedative effect compared to some other benzodiazepines.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older.
* Off-label uses may include other seizure types, anxiety disorders, and movement disorders, but these should be guided by specialist recommendations and available evidence.
## Adult Dosing
* **For LGS:** The usual starting dose is 5 mg twice daily.
* **Titration:** The dose can be increased by 5-10 mg per day every week, divided into two doses, until an effective dose is reached or intolerable side effects occur.
* **Maximum Dose:** Generally, 20 mg twice daily (40 mg/day). In some cases, doses up to 30 mg twice daily (60 mg/day) have been used under strict medical supervision for LGS.
## Pediatric Dosing
* **For LGS (2 years and older):**
* **Starting Dose:** 5 mg twice daily.
* **Titration:** Similar to adults, increase by 5 mg/day every week as needed, divided into two doses.
* **Maximum Dose (2-10 years):** 10 mg twice daily (20 mg/day).
* **Maximum Dose (>10 years):** 20 mg twice daily (40 mg/day). Doses up to 30 mg twice daily (60 mg/day) have been used for LGS under strict medical supervision.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosing guidelines are established, but lower doses and careful titration are recommended due to potential accumulation.
* **Renal Impairment:** No specific dose adjustment is recommended, but monitor for increased side effects.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory depression.
* Severe hepatic insufficiency.
## Adverse Effects
Common adverse effects include somnolence, drooling, constipation, decreased appetite, fatigue, and behavioral changes (e.g., aggression, irritability). Serious adverse effects include severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), withdrawal symptoms, and increased risk of suicidal thoughts or behavior.
## Key Drug Interactions
* **CNS Depressants:** Increased risk of sedation and respiratory depression when used with alcohol, opioids, other benzodiazepines, sedating antihistamines, antipsychotics, and other CNS depressants.
* **CYP2C19 Inhibitors/Inducers:** Clobazam is a substrate of CYP2C19. Strong inhibitors (e.g., fluconazole, voriconazole) may increase clobazam levels, and strong inducers (e.g., rifampin) may decrease levels.
* **CNS Stimulants:** May potentially reduce the efficacy of CNS stimulants used for ADHD.
## Monitoring
* **Efficacy:** Monitor seizure frequency and severity.
* **Safety:** Assess for somnolence, dizziness, behavioral changes, and signs of respiratory depression. Monitor for signs of withdrawal upon discontinuation.
* **Suicidal Ideation:** Patients should be monitored for any new or worsening suicidal thoughts or behaviors.
* **Skin Reactions:** Educate patients to report any rash or blistering immediately.
## Clinical Pearls
* Clobazam should be tapered gradually when discontinuing to avoid withdrawal symptoms.
* Due to its long half-life, it may be less prone to causing rebound seizures than shorter-acting benzodiazepines, but withdrawal can still be prolonged.
* Clobazam is often used as an adjunctive therapy and should not be used as monotherapy for epilepsy unless specifically indicated and guided by local protocol or specialist.
***
*Please verify current prescribing information and institutional protocols for the most up-to-date and comprehensive guidance.*
